The National Center for Advancing Translational Sciences (NCATS) issued four new funding opportunity announcements and provided information about partially developed pharmaceutical therapeutic candidates (referred to as “agents”) for researchers to crowdsource ideas for new uses. The announcements are part of the Center’s Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program, which matches researchers with a selection of pharmaceutical industry agents to help scientists explore new treatments for patients.

For these funding opportunities, NCATS collaborated with AstraZeneca, Janssen Research & Development, L.L.C., Pfizer Inc. and Sanofi to make 26 agents available. And for the first time in this program, these pharmaceutical companies have identified agents that are suitable for exploring pediatric indications.

Read the full announcement